4th Mar 2005 07:00
Oxford Biomedica PLC04 March 2005 FOR IMMEDIATE RELEASE 4 MARCH 2005 OXFORD BIOMEDICA: NOTICE OF FY2004 PRELIMINARY RESULTS Oxford, UK - 4 March 2005: Oxford BioMedica (LSE:OXB.L), the leading genetherapy company, announces that it will be releasing its preliminary results forthe twelve months ended 31 December 2004 on Monday, 21 March 2005. Meetings: An analyst briefing will be held at 10:00 am on the day followed by a pressbriefing which will commence at 11:30 am. The venue for both meetings will beBuchanan Communications, 107 Cheapside, London EC2V 6DN. Web cast: Simultaneously to the analyst briefing at 10.00 am, there will be a live audioweb cast of the results presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before the startof the briefing. This will also be available for replay shortly after thepresentation. -Ends- For further information, please contact:Oxford BioMedica plc:Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000Andrew Wood, Chief Financial Officer City/Financial Enquiries:Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Tel: +44 (0)20 7466 5000Communications Scientific/Trade Press Enquiries:Sue Charles/ Katja Stout/ Ashley Lilly Tel: +44 (0)20 7886 8150Northbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes an immunotherapy and a gene therapy in multiple Phase II trials, and apreclinical targeted antibody therapy in collaboration with Wyeth. Inneurotherapy, the Company's lead product is a gene therapy for Parkinson'sdisease, which is expected to enter clinical development in 2005, and fourfurther preclinical candidates. The Company is underpinned by over 80 patentfamilies, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 65 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham,Viragen, MolMed and Kiadis; and has licensed technology to a number of companiesincluding Merck & Co and Biogen Idec. Further information is available at www.oxfordbiomedica.co.uk. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica